Background: High sensitivity C-reactive protein (hsCRP) predicts myocardial dysfunction after acute coronary syndromes. We aimed to study the association of hsCRP estimation at first acute myocardial infarction (AMI) with myocardial dysfunction and heart failure.
Introduction
The development of heart failure after acute coronary syndromes (ACS) is the most common complication associated with a high mortality rate.
Study population andpatient enrollment
The study was approved by the College of Medicine Institutional Review Board committee. All patients signed the consent form with Arabic and English versions. The patient consent was written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.
A detailed history was recorded and clinical examination was performed. All information was recorded on a predesigned proforma. Inclusion criteria included adult patients of any sex with AMI. For the diagnosis of AMI and other ACS protocols we used standard criteria as previously reported. 12, 13 Heart failure was diagnosed on the basis of symptoms, clinical signs, and documented left ventricular impairment (left ventricular ejection fraction≤40%) according to the current guidelines. 14 At AMI, the Killip classification was used to evaluate patients for heart failure, and at follow up the New York Heart Association Functional Classification scores were recorded. Patients with associated systemic disorders like acute infections, stroke, acute diabetic status, rheumatic diseases, chronic liver diseases, renal failure, cancers, and sepsticemia, patients with an ongoing or recent infectious disorder, and patients with a surgical procedure in the past 3 months time were excluded. Of the 227 patients recruited, 181 patients had evidence of AMI on the basis of the standard criteria. The remaining 46 patients were used as a control. Among them, 31 had unstable angina, 9 had chronic CAD, and 6 turned out to be having nonischemic problems. Only 150 patients completed the study: 5 patients died during follow up and 26 patients did not turn up and were excluded from the study. Patients were divided into two groups based on a cutoff point of the mean value of hsCRP levels on admission, which was 10.05±12.68 mg/L. Group A had CRP<10 mg/L on admission while group B had CRP≥10 mg/L on admission.
Analytical details and assays
Venous blood samples were tested for lipid profile including total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), and hsCRP. TC, TG, LDL ,and HDL were analyzed by a Dimension autoanalyzer (USA). hsCRP assays were performed with the turbidimetric assay method (Quantex hsCRP kits) supplied by BIOKIT Spain using an Hitachi 911 autoanalyzer manufactured by ROCHE Diagnostics (Hoffmann-La Roche Ltd., Basel, Switzerland). The kit detected hsCRP in the range of 0.10-20.0 mg/L. We followed the American Heart Association criteria for measurement, evaluation, and expression of hsCRP.
15 Lp(a) was analyzed by turbidimetric immunoassay with the quantex Lp(a) kits supplied by BIOKIT Spain.
Patient follow up and study endpoints
Blood samples were taken for analysis of hsCRP on admission to hospital at first AMI in the acute phase (<12 hours from onset of symptoms) from the antecubital vein. After centrifugation, the serum was separated and stored at −70°C until assayed. 12 months after recruitment each patient was called for a complete clinical check-up and echocardiography was performed using standard procedures. The patients were followed up for recurrent events and complications that occurred after the first attack of AMI. The doctors examining the patients and those who performed the echocardiography were unaware of the hsCRP levels. In about 16 patients the echocardiographic images were technically not suitable and were discarded from the final data analysis. Any mortalities during this time, with dates and causes, were obtained from hospital records or from the patient's family doctor. 
Statistical analysis

Results
We prospectively examined the association of hsCRP with heart failure in patients with first myocardial infarction.
Clinical and demographic data details are expressed in detail for all CAD patients in Table 1 Table 1 also shows the mean peak cardiac enzymes attained. Among the peak cardiac enzymes, only AST levels were significantly high in AMI patients divided into low and high CRP groups based on a cutoff mean value of hsCRP level on admission (10.05±12.68 mg/L). The average time for the first sample was 7 h and 20 min in the low CRP group and was 6 h and 45 min in the high CRP group. Table 2 shows a comparison of clinical and demographic characteristics between AMI patients with low and high hsCRP levels. Serum AST levels were significantly higher in the high CRP group (p=0.0198), and also the diabetes mellitus frequency (p=0.0106). We observed significantly lower levels of ejection fraction at 1 year of follow up in patients of Group B (37.29±12.97) compared to Group A (43.85 ±11.77, p=0.0198) ( Table 3) .
The difference for Lp(a) levels was nonsignificant between the two groups (23.39±20.67 vs 28.43±28.25, p=0.2532). This was also the case for TC, TG, LDL, and HDL levels ( Table 4) .
Troponin (r=−0.382, p<0.001) and hsCRP (r=−0.283, p<0.01) levels on admission correlated negatively with ejection fraction (Table 5 ). 38.1% of patients had heart failure, with 23.6% in the high CRP group and 14.5% in the low CRP group (OR 2.4, CI=1.084-5.225, p=0.028). DovePress CRP levels at AMI had a specificity of 79% and sensitivity of 83% to predict heart failure at a cutoff level of 10 mg/L (Figure 1 ). Correlation of CRP at AMI with clinical characteristics, CAD severity, and lipid profile in all myocardial infarction patients is expressed in Tables 6 and 7 . CRP levels were correlated significantly with Killip scores at AMI (r=0.311, p=0.008) and clinical signs of severity scores at follow up (r=0.255, p=0.032). There was no relation of CRP with CAD severity determined by the Gensini score.
Discussion
This study reports that higher levels of CRP at admission in AMI patients predicts heart failure at follow up with an OR of about 2.4 (p<0.01). Inflammatory markers are important indicators for discrimination of different clinical forms of ACS. In one study, neutrophil-to-lymphocyte ratios (NLRs) were significantly higher in patients with AMI in relation to patients with UA. There was a positive correlation between the NLR and markers of myocardial necrosis, and between the NLR and CRP, indicating the importance of the NLR in the assessment of the extent of myocardial necrosis and inflammation severity. 15 We have reported previously that even in chronic stable CAD patients, higher levels of CRP are present. 16 Long-term risks of high CRP levels in ACS patients have been reported in a number of studies. 17, 18 After AMI in patients presenting with persistent ST elevation, high CRP levels predict worse outcomes. 19 The time course of hsCRP in STEMI differs from NSTEMI, which may be predictive of worse outcomes. 10 Suleiman et al 18 have reported similar results to our previous study that in AMI, the CRP levels obtained up to 24 h after symptom onset act as an independent marker of mortality and heart failure after 30 days. 20 hsCRP levels after AMI predicted emergence of heart failure 
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in a study by Stumpf et al. 7 Peak CRP is also a strong predictor of global and cardiovascular mortality during the following year after STEMI. 7 Bursi et al 21 reported in a recent study that CRP at admission to hospital is useful for predicting the time course of heart failure in patients with AMI. Obtaining peak hsCRP values is reported to be a strong independent predictor of global mortality and heart failurerelated mortality in the following year of follow up. 21 In line with our study is the report by Berton et al that measuring hsCRP on first day of AMI was independently associated with myocardial dysfunction, with heart failure indications in both models' age of patient, CK, past heart attacks of myocardial infarction, anterior site of AMI, and aldosterone levels all being other independent predictors for development of heart failure. When statin treatment was included in the models, the results remained virtually unchanged. Therefore, hsCRP measurement on admission to hospital significantly predicts the time course of heart failure in patients with AMI and is a strong independent predictor of global and heart failure mortality. 22 Acute phase levels of hsCRP prior to marked elevations of cardiac troponin I (cTnI) may make the body prime to respond to any necrotic or injured tissue. This evidence is supported by De Servi et al 23 depicting that in ACS patients there is a large variability in hsCRP levels, with those presenting with high hsCRP titers at baseline probably more hyperresponsive to circulating cTnI. Thus, myocardial necrosis, indicated by troponin increase, is the strongest stimulus for CRP increase in AMI, causing a disproportionate increase of troponin. Thus, the highest CRP values during ACS are likely to be observed in patients with already elevated CRP values at baseline (increasing the probability of mortality risk and subsequent attacks) and the highest troponin values (increasing the probability of mortality risk but not of subsequent heart attacks). The study by Kavsak et al 24 indicated that high CRP titers, independent of the subjects' age, gender, and cTnI concentrations, predict long-term heart failure and mortality. 24 Not only did CRP≥15 mg/L identify patients with heart failure at entry, it also predicted worsening of left ventricular function in patients presenting without clinical signs of heart failure at entry. Furthermore, in agreement with their results, CRP levels were a significant predictor of heart failure in our study in patients who did not have had any signs of heart failure at their first myocardial infarction.
Although the exact role of CRP requires further exploration, our study focusing on hsCRP measurements within the first 3 days after AMI may prove useful for identification and prediction in patients who are at greater risk of heart failure and mortality. Scirica et al have reported that both hsCRP and BNP measured 30 days after ACS are independently associated with the risk of heart failure and cardiovascular mortality, with the greatest risk occurring when both markers are simultaneously high. 6 CRP has been a marker of interest as a predictor of heart failure and pharmacological treatment benefits. In a metaanalysis by Zhou et al, 25 trimetazidine administration in heart failure patients significantly improved symptoms and echocardiographic functions and improved CRP levels. 25 cTnI and cardiac troponin C along with CRP are related to heart failure and left ventricular hypertrophy in chronic renal failure, which may prove useful in risk stratification of these subjects. 26 Levocarnitine treatment has been shown to have a beneficial effect on hsCRP, cardiac troponin, and left ventricular diastolic dysfunction. 27 Low-grade chronic inflammation indicated by CRP is reported to be a significant contributor to left atrial stiffening regardless of left ventricular size. 28 
Conclusions
CRP levels on admission to hospital after first myocardial infarction are associated with an increased risk of heart failure. Our study shows that inflammatory processes play an independent role in the development of heart failure after myocardial infarction. CRP is a useful marker for predicting the time course of heart failure in patients with AMI. Thus, hsCRP measurements may assist in risk stratification after myocardial infarction. Measurement of hsCRP levels in patients earlier in AMI could help clinicians to discriminate those patients who are at increased risk of heart failure in the future.
